Gabapentin Tablet
Product Images NDC 82804-249

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 82804-249). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

82804-249-90 (800 mg 100s)

This is a description of Gabapentin 800mg tablets, with a prescription label including the NDC number, manufacturer details (Ascent Pharmaceuticals, Inc.), storage instructions, and other important information. The tablets are bisected with '3' on one side and bisect on the other side. They are intended for oral use. The tablets are packaged by Proficient Rx LP and come in a pack of 90 tablets. The lot number, serial number, and expiration date are provided for tracking and safety purposes. Remember to keep the medication out of the reach of children.*

FDA Label Image

Clcr (Equation)

This text provides formulas for calculating creatinine clearance and adjusting for gender. The creatinine clearance calculation involves multiplying 140 minus the age in years by the weight in kilograms. Additionally, the formula for female patients involves multiplying the result by 0.85. Another formula is given for creatinine clearance, which involves multiplying 72 by the serum creatinine level in mg/dL.*

FDA Label Image

Figure-1 (Figure1)

This is a figure showing the weekly mean pain scores observed in the intent-to-treat (ITT) population for Study 1. The graph includes data points for different time points and displays the pain scores over time for the treatment group receiving Gabapentin at a dose of 3500 iy. The baseline pain score and scores for weeks 1 to 8 are shown on the graph.*

FDA Label Image

Figure-2 (Figure2)

FDA Label Image

Figure-3 (Figure3)

The text provides information about the proportion of responders in controlled post-herpetic neuralgia (PHN) studies. It indicates the percentage of patients with more than a 50% reduction in pain score at the endpoint of the study. Study 1 and Study 2 are mentioned, along with different dosage levels of GBP (Gabapentin) and PBO (Placebo).*

FDA Label Image

Figure-4 (Figure4)

FDA Label Image

Struc (Struct)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.